Retatrutide Pharmacogenomics: How Genetic Variability May Shape Triple-Agonist Response

How Retatrutide Works: Three Receptors, Three Genes

Retatrutide is a single peptide engineered to activate three distinct hormone receptors simultaneously. It binds the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP1R), and the glucagon receptor (GCGR). Each receptor is encoded by its own gene on a different chromosome, and each gene carries polymorphisms that alter receptor expression, binding affinity, or downstream signaling.

In the phase 2 trial published by Jastreboff et al. in the New England Journal of Medicine, participants receiving the 12 mg dose lost a mean of 24.2% body weight at 48 weeks, compared with 2.1% in the placebo group 1. That mean, however, masked striking individual variation. Some participants lost over 30% of their starting weight. Others on the same dose lost under 10%. Diet, adherence, and baseline BMI explain part of this spread, but genetic differences in receptor biology likely contribute as well.

The triple-agonist design makes retatrutide's pharmacogenomic profile more complex than single-target GLP-1 receptor agonists like semaglutide or liraglutide. A patient carrying a loss-of-function variant in one receptor gene might still respond strongly through the other two pathways. This built-in redundancy could buffer against single-gene effects, or it could create unexpected interaction patterns between variant receptors 2.

GLP1R Variants and Incretin-Class Response

The GLP-1 receptor gene (GLP1R, chromosome 6p21) contains several nonsynonymous single-nucleotide polymorphisms that change receptor function. The most studied is rs6923761, which encodes a glycine-to-serine substitution at position 168 (Gly168Ser). Carriers of the Ser168 allele show reduced receptor signaling in cell-based assays and, in clinical cohorts, exhibit attenuated weight loss and glycemic improvement on GLP-1 receptor agonists 3.

A 2015 pharmacogenetic analysis of 116 patients with type 2 diabetes treated with liraglutide found that Ser168 carriers had 0.4% less HbA1c reduction over 14 weeks compared with Gly168 homozygotes 3. The allele frequency varies by ancestry: approximately 25% in European populations, 12% in East Asian populations, and 30% in some Latin American cohorts, according to gnomAD data 4.

Another variant, rs3765467 (Arg131Gln), reduces GLP-1 binding affinity by roughly 50% in vitro 5. This variant is rare in European populations (minor allele frequency <2%) but reaches 8-10% in East Asian populations, making it potentially more relevant for pharmacogenomic screening in those groups.

For retatrutide specifically, no published pharmacogenomic data on GLP1R variants exist yet. But because the drug's GLP-1 receptor engagement uses the same orthosteric binding site as endogenous GLP-1, the same receptor variants that modulate liraglutide and semaglutide response are expected to influence at least one axis of retatrutide's triple action.

GIPR Polymorphisms: The Least-Studied Pathway

The GIP receptor gene (GIPR, chromosome 19q13.32) harbors several functional variants, the most studied being rs10423928. This intronic variant is associated with reduced GIP-stimulated insulin secretion and, paradoxically, with lower BMI in population-level genome-wide association studies 6. Carriers of the T allele at rs10423928 show a 15-20% reduction in meal-stimulated GIP response.

A coding variant, Glu354Gln (rs1800437), alters receptor internalization kinetics. The Gln354 allele is carried by approximately 18% of Europeans and is associated with reduced beta-cell response to GIP infusion 7. Whether this variant diminishes the GIP-mediated component of retatrutide's weight-loss effect remains untested, but the biological plausibility is strong.

The GIPR pathway presents a unique pharmacogenomic question. Tirzepatide, a dual GIP/GLP-1 agonist, demonstrated that GIP receptor activation contributes meaningfully to weight loss beyond what GLP-1 agonism alone achieves 8. If a patient carries a GIPR loss-of-function variant, the incremental benefit of retatrutide's GIP component over a pure GLP-1 agonist could be reduced. That patient might achieve similar results with semaglutide at lower cost. This is speculative but represents exactly the kind of clinical question pharmacogenomics could eventually answer.

GCGR Variants: The Glucagon Component

The glucagon receptor gene (GCGR, chromosome 17q25.3) is the third pharmacogenomic variable in retatrutide's equation. A missense variant, Gly40Ser (rs1801483), has been associated with type 2 diabetes risk in multiple populations. Carriers show altered hepatic glucose output and modified glucagon clearance 9.

Glucagon receptor activation drives energy expenditure through hepatic lipid oxidation and thermogenesis. Retatrutide's glucagon agonism is what distinguishes it from tirzepatide and is hypothesized to account for the additional 5-8 percentage points of weight loss seen in the phase 2 data 1. Patients with GCGR variants that reduce receptor sensitivity could theoretically lose this metabolic advantage.

A rarer variant, Thr8Ile, has been identified in Inuit populations at frequencies approaching 4% and is linked to altered lipid metabolism 10. As retatrutide moves into global phase 3 trials, population-specific GCGR variants will become increasingly relevant to understanding response heterogeneity.

Dr. Daniel Drucker, a pioneer in incretin biology at the University of Toronto, has noted: "The glucagon receptor adds a metabolic dimension that GLP-1 agonists alone cannot access. Understanding who responds to that dimension, and why, is one of the more important pharmacogenomic questions in obesity medicine right now" 2.

Obesity-Risk Loci and Treatment Response

Beyond receptor genes, common obesity-susceptibility variants influence how patients respond to any weight-management intervention, pharmacologic or otherwise. Two loci deserve specific attention in the context of retatrutide.

FTO rs9939609. The fat mass and obesity-associated gene variant is carried by roughly 42% of European-ancestry individuals (at least one risk allele). FTO risk-allele carriers gain more weight over their lifetimes but, in several studies, also lose more absolute weight on GLP-1 receptor agonists 11. A 2013 meta-analysis of 9,563 participants across lifestyle and pharmacologic interventions found that AA homozygotes at rs9939609 lost 0.5 kg more than TT homozygotes on average, though effect sizes varied by intervention type 11.

MC4R rs17782313. Melanocortin-4 receptor variants are the most common monogenic cause of severe early-onset obesity, but common noncoding variants also modulate appetite regulation. The C allele at rs17782313 (frequency ~24% in European populations) is associated with increased hunger scores. Whether MC4R status interacts with retatrutide's appetite-suppressing GLP-1 component is unknown, but preclinical models suggest MC4R-deficient animals show blunted anorectic response to GLP-1 receptor agonists 12.

Dr. Ania Jastreboff, lead investigator of the retatrutide phase 2 trial at Yale, stated: "We saw a wide range of individual responses. Identifying the biological drivers of that variability, including genetic factors, will be a priority as the program advances" 1.

Why Retatrutide Is Not Subject to CYP450 Pharmacogenomics

A common assumption when hearing "pharmacogenomics" is that cytochrome P450 enzyme variants will dictate drug metabolism. That assumption does not apply here. Retatrutide is a 39-amino-acid peptide that is degraded by proteolytic enzymes, not hepatic CYP450 isoforms 1. Variants in CYP2D6, CYP2C19, CYP3A4, and other classic pharmacogenes are not expected to alter retatrutide exposure.

This distinction matters. It means pharmacogenomic testing panels designed for small-molecule drugs (the kind increasingly ordered in psychiatry and cardiology) will not provide useful information about retatrutide response. Any future pharmacogenomic test for this drug will need to focus on pharmacodynamic targets: receptor genes, signaling pathway components, and appetite-regulation loci 13.

The fatty-acid side chain that extends retatrutide's half-life (enabling once-weekly dosing) binds to albumin, but albumin genetic variants that alter drug binding are extremely rare and clinically insignificant for peptide therapeutics at current doses 13.

Tolerability Pharmacogenomics: Nausea, Vomiting, and GI Side Effects

Gastrointestinal side effects are the primary tolerability concern with incretin-based therapies. In the retatrutide phase 2 trial, nausea occurred in 16.4% to 45.0% of participants across dose groups (dose-dependent), and vomiting in 8.5% to 17.5% 1. Some patients tolerated rapid dose escalation without any GI complaints. Others required dose holds at lower levels.

Candidate genes for GI tolerability include GLP1R itself (variants affecting receptor desensitization kinetics), COMT (catechol-O-methyltransferase, which modulates nausea via dopaminergic pathways), and OPRM1 (the mu-opioid receptor gene, where the Asn40Asp variant rs1799971 has been linked to post-operative nausea susceptibility) 14.

No published data directly link any genetic variant to GI tolerance of GLP-1 or GIP agonists. This gap represents a high-value target for pharmacogenomic substudies in the retatrutide phase 3 program. Identifying patients genetically predisposed to severe nausea could allow clinicians to select slower titration schedules or prophylactic antiemetics at the outset.

What to Expect From Phase 3 Pharmacogenomic Data

Eli Lilly's phase 3 program for retatrutide includes multiple large trials across obesity and type 2 diabetes populations. These trials will likely collect DNA samples for pharmacogenomic analysis, as Lilly did with tirzepatide in the SURMOUNT and SURPASS programs. Prospective genome-wide association analyses across thousands of participants could identify novel loci that predict response magnitude and tolerability 15.

The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity acknowledges that "genetic testing to guide obesity pharmacotherapy selection is not yet supported by sufficient evidence for routine clinical use, but should be a research priority" 16.

Until retatrutide-specific data emerge, clinicians should document individual response patterns carefully, especially in patients who show unexpectedly low efficacy or high GI sensitivity despite adequate dosing and adherence. These cases are the clinical phenotypes that pharmacogenomic studies will eventually need to explain.

Patients with MC4R or PCSK1 pathogenic variants causing monogenic obesity may respond differently to incretin-based therapies. The ongoing EMANATE trial (NCT05813925) is evaluating setmelanotide for MC4R-pathway obesity, and outcomes from that program could inform whether retatrutide's GLP-1 component works independently of melanocortin signaling or requires an intact MC4R pathway for full anorectic effect 12.